<code id='B6060B2DDB'></code><style id='B6060B2DDB'></style>
    • <acronym id='B6060B2DDB'></acronym>
      <center id='B6060B2DDB'><center id='B6060B2DDB'><tfoot id='B6060B2DDB'></tfoot></center><abbr id='B6060B2DDB'><dir id='B6060B2DDB'><tfoot id='B6060B2DDB'></tfoot><noframes id='B6060B2DDB'>

    • <optgroup id='B6060B2DDB'><strike id='B6060B2DDB'><sup id='B6060B2DDB'></sup></strike><code id='B6060B2DDB'></code></optgroup>
        1. <b id='B6060B2DDB'><label id='B6060B2DDB'><select id='B6060B2DDB'><dt id='B6060B2DDB'><span id='B6060B2DDB'></span></dt></select></label></b><u id='B6060B2DDB'></u>
          <i id='B6060B2DDB'><strike id='B6060B2DDB'><tt id='B6060B2DDB'><pre id='B6060B2DDB'></pre></tt></strike></i>

          Home / comprehensive / knowledge

          knowledge


          knowledge

          author:entertainment    Page View:554
          Adobe

          LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

          The deal includes up to another $400 million in payments if certain milestones are met.

          advertisement

          Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In